However, trametinib-resistant BRAFV600 melanomas with activated ERK1/2 were resistant to the Mcl-1 inhibitor S63845 because of ERK1/2-mediated upregulation of Mcl-1 and suppression of Bim, while cells with high Bim levels but low ERK1/2 and Mcl-1 activities were especially sensitive to Mcl-1 inhibition[66]. This evidence concerns the gene MAPK3 and melanoma.